Zeiss Medical Technology has received CE mark approval from the European Commission for its CIRRUS PathFinder, a revolutionary AI-enhanced clinical support tool. This innovative platform uses advanced artificial intelligence to streamline imaging and clinical workflows, significantly improving optical coherence tomography (OCT) interpretation through a proprietary deep learning algorithm. The tool automatically identifies anomalies in OCT-B scans while enhancing OCT angiography (OCTA) image quality and multilayer segmentation. Zeiss emphasizes the all-in-one nature of CIRRUS PathFinder, eliminating the need for data exports or third-party platforms. It flags areas needing further imaging during acquisition and enhances vascular structure visualization, leading to faster, informed diagnostics for enhanced patient care. These capabilities position Zeiss at the forefront of AI-driven ophthalmic solutions. As part of a broader initiative, Zeiss is committed to integrated digital workflows, further exemplified by the recent launch of its cloud-based Zeiss Research Data Platform.
Source link
